Synovial apoptosis in temporomandibular joint disc displacement without reduction

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 108, Issue 5, 2009, Pages 693-698

  Imirzalioǧlu, Pervin ^a   Uçkan, Sina ^a   Güler, Nurhan ^b   Haberal, Ayşegül ^a   Uçkan, Duygu ^c  

^a BASKENT UNIVERSITY   (Turkey)

^b YEDITEPE UNIVERSITY   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS PROTEIN, HUMAN; NUCLEAR MATRIX PROTEIN;

ADULT; APOPTOSIS; ARTICLE; CHEMISTRY; DISLOCATION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; OSTEOARTHRITIS; PARACENTESIS; PATHOLOGY; PATHOPHYSIOLOGY; SYNOVIAL FLUID; SYNOVIUM; TEMPOROMANDIBULAR JOINT; TEMPOROMANDIBULAR JOINT DISORDER;

ADULT; ANTIGENS, CD95; APOPTOSIS; DISLOCATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR MATRIX-ASSOCIATED PROTEINS; OSTEOARTHRITIS; PARACENTESIS; SYNOVIAL FLUID; SYNOVIAL MEMBRANE; TEMPOROMANDIBULAR JOINT DISK; TEMPOROMANDIBULAR JOINT DISORDERS; YOUNG ADULT;

EID: 72149099347     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2009.05.030     Document Type: Article

References (40)

1. Kopp S., Carlsson G.E., Hansson T., and Oberg T. Degenerative disease in the temporomandibular, metatarsophalangeal and sternoclavicular joints. An autopsy study. Acta Odontol Scand 34 (1976) 23-32
2. de Bont L.G.M., Boering G., Liem R.S.B., Eulderink F., and Westesson P.L. Osteoarthrositis and internal derangement of the temporomandibular joint: A light microscopic study. J Oral Maxillofac Surg 44 (1986) 634-643
3. Stegenga B., de Bont L.G.M., and Boering G. Osteoartrosis as the cause of craniomandibular pain and dysfunction: a unifying concept. J Oral Maxillofac Surg 47 (1989) 249-256
4. Westesson P.L., and Rohlin M. Internal derangement related to osteoarthrosis in temporomandibular joint autopsy specimens. Oral Surg 57 (1984) 17-22
5. Stegenga B., de Bont G.M., Boering G., and van Willigen J.D. Tissue responses to degenerative changes in the temporomandibular joint: a review. J Oral Maxillofac Surg 49 (1991) 1079-1088
6. Larheim T.A., Katzberg R.W., Westesson P.L., Tallents R.H., and Moss M.E. MR evidence of temporomandibular joint fluid and condyle marrow alterations: occurrence in asymptomatic volunteers and symptomatic patients. Int J Oral Maxillofac Surg 30 (2001) 113-117
7. Güler N., Yatmaz P., Ataoǧlu H., Uçkan S., and Emlik D. Temporomandibular internal derangement: correlation of mr findings with clinical symptoms of pain and joint sounds in patients with bruxing behaviour. DentoMaxfac Radiol 32 (2003) 304-309
8. de Leeuw R., Boering G., Stegenga B., and de Bont L.G. Radiographic signs of the temporomandibular joint osteoarthrosis and internal derangement 30 years after nonsurgical treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 79 (1995) 382-392
9. Milam S.B., and Schmitt J.P. Molecular biology of temporomandibular joint disorders: proposed mechanisms of disease. J Oral Maxillofac Surg 53 (1995) 1448-1454
10. Wakisaka S., Suzuki W., Takeba Y., Shimoyama Y., Nagafuchi H., and Takeno N. Modulation by proinflammatory cytokines of Fas/Fas ligand-medated apoptotic cell death of synovial cells in patients with rheumatoid arthtitis (RA). Clin Exp Immunol 114 (1998) 119-127
11. Kerr J.F.R., Wyllie A.H., and Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26 (1972) 239-257
12. Wyllie A.H., Kerr J.F.R., and Currie A.R. Cell death: the significance of apoptosis. Int Rev Cytol 68 (1980) 251-306
13. Majno G., and Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 146 (1995) 3-15
14. Suda T., Takahashi T., Golstein P., and Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75 (1993) 1169-1178
15. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-371
16. Machner A., Bajer A., Willie A., Drynda S., Pap G., Drynda A., et al. Higher susceptibility to Fas ligand induced apoptosis and alterd modulation of cell death by tumor necrosis factor alfa in periarticular tenocytes from patients with knee joint osteoarthritis. Arthritis Res Ther 5 (2003) 253-261
17. Heaney M.L., and Golde D.W. Soluble cytokine receptors. Blood 87 (1996) 847-857
18. Hasunuma T., Kayagaki N., Asahara H., Motokawa S., Kobato T., Yagita H., et al. Accumulation of soluble Fas in inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum 40 (1997) 80-86
19. Nozawa K., Kayagaki N., Tokano Y., Yagita H., Okumura K., and Hasimoto H. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases. Arthritis Rheum 40 (1997) 1126-1129
20. Berezney R., and Coffey D.S. Identification of a nuclear protein matrix. Biochem Biophys Res Commun 60 (1974) 1410-1417
21. Pardoll D.M., Vogelstein B., and Coffey D.S. A fixed site of DNA replication in eucaryotic cells. Cell 19 (1980) 527-536
22. Zeitlin S., Parent A., Silverstein S., and Estradiatis A. Pre-mRNA splicing and the nuclear matrix. Mol Cell Biol 7 (1987) 111-120
23. Miller T.E., Beausang L.A., Winchell L.F., Winchell L.F., and Lidgard G.P. Detection of nuclear matrix proteins in serum from cancer patients. Cancer Res 52 (1992) 422-427
24. Gu Z., Shibata T., Cao Z., Feng J., and Hu J. Chondrocyte apoptosis in tempormandibular joints with disc displacement. J Oral Maxillofacial Surg 60 (2002) 1026-1031
25. Nagai H., Kumamoto H., Fukuda M., and Takahashi T. Inducible nitric oxide syntase and apoptosis-related factors in the synovial tissues of in tempormandibular joints with internal derangement and osteoarthritis. J Oral Maxillofacial Surg 61 (2003) 801-807
26. de Leeuw R., Boering G., van der Kuijl B., and Steganga B. Hard and soft tissue imaging of the temporomandibular joint 30 years after diagnosis of osteoarthrosis and internal derangement. J Oral Maxillofac Surg 54 (1996) 1270-1280
27. Chou C.T., Yang J.S., and Lee M.R. Apoptosis in rheumatoid arthritis-expression of Fas, Fas-L, p53, and Bcl-2 in rheumatoid synovial tissues. J Pathol 193 (2001) 110-116
28. Hashimoto S., Ochs R.L., and KomLotz M. Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis. Arthritis Rheum 41 (1998) 1632-1638
29. Sah R.L., Chen A.C., Chen S.S., Li K.W., Dimicco M.A., Kurtis M.S., et al. Articular cartilage repair. In: Koopman W. (Ed). Arthritis and allied conditions-a textbook of rheumatology (2001), Lippincott Williams & Wilkins, Philadelphia, PA 2264-2273
30. Carson D.A., and Riberio J.M. Apoptosis and disease. Lancet 341 (1993) 1251-1254
31. Okura T., Watanabe S., Jiang Y., Nakamura M., Takata Y., Yang Z.H., et al. Soluble Fas ligand and atherosclerosis in hypertensive patients. J Hypertens 20 (2002) 895-898
32. Saitoh T., Karasawa M., Sakuraya M., Norio N., Junko T., Shirakawa K., et al. Improvement of extrathymic T cell type of large granular lymphocyte (LGL) leukemia by cyclosporin A: the serum level of Fas ligand is a marker of LGL leukemia activity. Eur J Haematol 65 (2000) 272-275
33. Kanda Y., Tanaka Y., Shirakawa K., Yatomi T., Nakamura N., Kami M., et al. Increased soluble Fas-ligand in sera of bone marrow transplant recipients with acute graft-versus-host disease. Bone Marrow Transplant 22 (1998) 751-754
34. Li N.L., Nie H., Yu Q.W., Zhang J.Y., Ma A.L., Shen B.H., et al. Role of soluble Fas ligand in autoimmune diseases. World J Gastroenterol 10 (2004) 3151-3156
35. Kim W.U., Kwok S.K., Hong K.H., Yoo S.A., Kong J.S., Choe J., et al. Soluble Fas ligand inhibits angiogenesis in rheumatoid. arthritis Arthritis Res Ther 9 2 (2007) R42
36. Kuwano K., Kawasaki M., Maeyama T., Hagimoto N., Nakamura N., Shirakawa K., et al. Soluble form of Fas and Fas ligand in BAL fluid with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia. Chest 118 (2000) 451-458
37. Wetzig T., Petri J.B., Mittag M., and Haustein U.F. Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis. Arch Dermatol Res 290 (1998) 187-190
38. Iwama H., Akatsu H., Kuretake S., Tohma J., and Nakamura N. Serum concentration of soluble Fas antigen and soluble Fas ligand in mother and newborn. Arch Gynekol Obstet 263 (2000) 108-110
39. Sano H., Asano K., Minatoguchi S., Hiraoka J., Fujisawa K., Nishigaki K., et al. Plasma soluble fas and soluble fasligand in chronic glomerulonephritis. Nephron 80 (1998) 153-161
40. Hara H., Morita Y., Sato R., and Ban Y. Circulating nuclear matrix protein in Graves' disease. Endocr J 49 (2002) 343-347